CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis

NYSE:CRL • US1598641074

169.595 USD
+5.35 (+3.26%)
Last: Feb 20, 2026, 03:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 58 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • CRL had positive earnings in the past year.
  • CRL had a positive operating cash flow in the past year.
  • Of the past 5 years CRL 4 years were profitable.
  • Of the past 5 years CRL 4 years had a positive operating cash flow.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1.2 Ratios

  • CRL has a better Return On Assets (-1.11%) than 60.34% of its industry peers.
  • With a decent Return On Equity value of -2.45%, CRL is doing good in the industry, outperforming 62.07% of the companies in the same industry.
  • The Return On Invested Capital of CRL (5.84%) is better than 75.86% of its industry peers.
  • CRL had an Average Return On Invested Capital over the past 3 years of 7.32%. This is below the industry average of 12.04%.
Industry RankSector Rank
ROA -1.11%
ROE -2.45%
ROIC 5.84%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • CRL's Profit Margin has declined in the last couple of years.
  • CRL has a Operating Margin of 11.73%. This is in the better half of the industry: CRL outperforms 72.41% of its industry peers.
  • In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 34.68%, CRL is doing worse than 62.07% of the companies in the same industry.
  • CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 11.73%
PM (TTM) N/A
GM 34.68%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for CRL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 2.35 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.35, CRL is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
  • The Debt to FCF ratio of CRL is 4.02, which is a neutral value as it means it would take CRL, 4.02 years of fcf income to pay off all of its debts.
  • CRL has a Debt to FCF ratio of 4.02. This is in the better half of the industry: CRL outperforms 72.41% of its industry peers.
  • A Debt/Equity ratio of 0.64 indicates that CRL is somewhat dependend on debt financing.
  • The Debt to Equity ratio of CRL (0.64) is worse than 70.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF 4.02
Altman-Z 2.35
ROIC/WACC0.55
WACC10.53%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.37. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • CRL's Current ratio of 1.37 is on the low side compared to the rest of the industry. CRL is outperformed by 77.59% of its industry peers.
  • CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • CRL has a worse Quick ratio (1.10) than 75.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.1
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for CRL have decreased by -0.39% in the last year.
  • The Earnings Per Share has been growing slightly by 4.78% on average over the past years.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.83%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.70% on average over the next years. This is quite good.
  • Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 3.26% on average per year.
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.50 indicates a correct valuation of CRL.
  • CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 91.38% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.09, CRL is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 15.44 indicates a correct valuation of CRL.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 91.38% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.98, CRL is valued a bit cheaper.
Industry RankSector Rank
PE 16.5
Fwd PE 15.44
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.83% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CRL is valued cheaply inside the industry as 91.38% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.35
EV/EBITDA 11.19
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.4
PEG (5Y)3.45
EPS Next 2Y8.98%
EPS Next 3Y8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHARLES RIVER LABORATORIES

NYSE:CRL (2/20/2026, 3:42:06 PM)

169.595

+5.35 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners107.25%
Inst Owner Change3.51%
Ins Owners0.89%
Ins Owner Change4.34%
Market Cap8.35B
Revenue(TTM)N/A
Net Income(TTM)-83.48M
Analysts78.26
Price Target221.43 (30.56%)
Short Float %5.53%
Short Ratio3.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.28%
Min EPS beat(2)2.88%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)10.51%
Min EPS beat(4)2.88%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.19%
EPS beat(12)12
Avg EPS beat(12)8.5%
EPS beat(16)16
Avg EPS beat(16)6.77%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)0.38%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.12%
Min Revenue beat(4)0.38%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.53%
Revenue beat(12)10
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)1.25%
PT rev (1m)9.96%
PT rev (3m)14.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)0.47%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.4%
Valuation
Industry RankSector Rank
PE 16.5
Fwd PE 15.44
P/S 2.07
P/FCF 15.35
P/OCF 11.14
P/B 2.45
P/tB N/A
EV/EBITDA 11.19
EPS(TTM)10.28
EY6.06%
EPS(NY)10.99
Fwd EY6.48%
FCF(TTM)11.05
FCFY6.51%
OCF(TTM)15.23
OCFY8.98%
SpS81.75
BVpS69.19
TBVpS-1.79
PEG (NY)2.4
PEG (5Y)3.45
Graham Number126.5
Profitability
Industry RankSector Rank
ROA -1.11%
ROE -2.45%
ROCE 7.39%
ROIC 5.84%
ROICexc 6.03%
ROICexgc 13.86%
OM 11.73%
PM (TTM) N/A
GM 34.68%
FCFM 13.51%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF 4.02
Debt/EBITDA 2.43
Cap/Depr 48.19%
Cap/Sales 5.12%
Interest Coverage 4.36
Cash Conversion 83.34%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.1
Altman-Z 2.35
F-Score4
WACC10.53%
ROIC/WACC0.55
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.83%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
EBIT growth 1Y-22.72%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year30.13%
EBIT Next 3Y11.84%
EBIT Next 5Y9.97%
FCF growth 1Y47.54%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.42%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%

CHARLES RIVER LABORATORIES / CRL FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


How profitable is CHARLES RIVER LABORATORIES (CRL) stock?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for CRL stock?

The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 6.87% in the next year.